207 related articles for article (PubMed ID: 35912837)
41. Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment.
Leon-Castillo A; Horeweg N; Peters EEM; Rutten T; Ter Haar N; Smit VTHBM; Kroon CD; Boennelycke M; Hogdall E; Hogdall C; Nout RRA; Creutzberg CL; Ortoft G; Bosse T
Gynecol Oncol; 2022 Mar; 164(3):577-586. PubMed ID: 35078648
[TBL] [Abstract][Full Text] [Related]
42. Patterns of recurrence and outcomes in surgically treated women with endometrial cancer according to ESMO-ESGO-ESTRO Consensus Conference risk groups: Results from the FRANCOGYN study Group.
Bendifallah S; Ouldamer L; Lavoue V; Canlorbe G; Raimond E; Coutant C; Graesslin O; Touboul C; Collinet P; Daraï E; Ballester M;
Gynecol Oncol; 2017 Jan; 144(1):107-112. PubMed ID: 27789083
[TBL] [Abstract][Full Text] [Related]
43. The brave new world of endometrial cancer : Future implications for adjuvant treatment decisions.
Marnitz S; Waltar T; Köhler C; Mustea A; Schömig-Markiefka B
Strahlenther Onkol; 2020 Nov; 196(11):963-972. PubMed ID: 32430662
[TBL] [Abstract][Full Text] [Related]
44. Immune checkpoint inhibitors for recurrent endometrial cancer.
Mutlu L; Harold J; Tymon-Rosario J; Santin AD
Expert Rev Anticancer Ther; 2022 Mar; 22(3):249-258. PubMed ID: 35176955
[TBL] [Abstract][Full Text] [Related]
45. Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy.
van den Heerik ASVM; Horeweg N; de Boer SM; Bosse T; Creutzberg CL
Int J Gynecol Cancer; 2021 Apr; 31(4):594-604. PubMed ID: 33082238
[TBL] [Abstract][Full Text] [Related]
46. SATEN III-Splitting Adjuvant Treatment of stage III ENdometrial cancers: an international, multicenter study.
Kahramanoglu I; Meydanli MM; Taranenka S; Ayhan A; Salman C; Sanci M; Demirkiran F; Ortac F; Haidopoulos D; Sukhin V; Kaidarova D; Stepanyan A; Farazaneh F; Aliyev S; Ulrikh E; Kurdiani D; Yalcin İ; Mavrichev S; Akilli H; Sarı ME; Pletnev A; Aslan K; Bese T; Kairbayev M; Vlachos D; Gultekin M
Int J Gynecol Cancer; 2019 Oct; 29(8):1271-1279. PubMed ID: 31481453
[TBL] [Abstract][Full Text] [Related]
47. Molecular characterization of endometrial cancer and therapeutic implications.
Chang Z; Talukdar S; Mullany SA; Winterhoff B
Curr Opin Obstet Gynecol; 2019 Feb; 31(1):24-30. PubMed ID: 30507624
[TBL] [Abstract][Full Text] [Related]
48. Management Strategies for Recurrent Endometrial Cancer.
Connor EV; Rose PG
Expert Rev Anticancer Ther; 2018 Sep; 18(9):873-885. PubMed ID: 29972650
[TBL] [Abstract][Full Text] [Related]
49. Recent and current Phase II clinical trials in endometrial cancer: review of the state of art.
Lheureux S; Wilson M; Mackay HJ
Expert Opin Investig Drugs; 2014 Jun; 23(6):773-92. PubMed ID: 24717108
[TBL] [Abstract][Full Text] [Related]
50. Adjuvant chemotherapy for endometrial cancer.
Tangjitgamol S; See HT; Kavanagh J
Int J Gynecol Cancer; 2011 Jul; 21(5):885-95. PubMed ID: 21697679
[TBL] [Abstract][Full Text] [Related]
51. Evolution of adjuvant treatment in endometrial cancer-no evidence and new questions?
Marnitz S; Köhler C; Gharbi N; Kunze S; Jablonska K; Herter J
Strahlenther Onkol; 2018 Nov; 194(11):965-974. PubMed ID: 30112692
[TBL] [Abstract][Full Text] [Related]
52. Systemic therapy for recurrent endometrial cancer: a review of North American trials.
Dellinger TH; Monk BJ
Expert Rev Anticancer Ther; 2009 Jul; 9(7):905-16. PubMed ID: 19589030
[TBL] [Abstract][Full Text] [Related]
53. Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma.
Vale CL; Tierney J; Bull SJ; Symonds PR
Cochrane Database Syst Rev; 2012 Aug; 2012(8):CD003915. PubMed ID: 22895938
[TBL] [Abstract][Full Text] [Related]
54. Adjuvant chemotherapy for endometrial cancer: unproven.
Creutzberg CL
Int J Gynecol Cancer; 2010 Oct; 20(11 Suppl 2):S60-3. PubMed ID: 20975364
[TBL] [Abstract][Full Text] [Related]
55. Adjuvant treatment of advanced-stage endometrial cancer.
Lee NK
Clin Obstet Gynecol; 2011 Jun; 54(2):256-65. PubMed ID: 21508695
[TBL] [Abstract][Full Text] [Related]
56. [Molecular-integrated risk profile: An opportunity for therapeutic de-escalation in intermediate and high-intermediate risk endometrial cancer].
Espenel S; Pointreau Y; Genestie C; Durdux C; Haie-Meder C; Chargari C
Cancer Radiother; 2022 Oct; 26(6-7):931-937. PubMed ID: 36031498
[TBL] [Abstract][Full Text] [Related]
57. Adjuvant therapy for high-risk endometrial cancer: recent evidence and future directions.
De Boer SM; Nout RA; Bosse T; Creutzberg CL
Expert Rev Anticancer Ther; 2019 Jan; 19(1):51-60. PubMed ID: 30295094
[TBL] [Abstract][Full Text] [Related]
58. SEOM guidelines for endometrial cancer.
Oaknin A; Rodríguez-Freixinós V; Díaz de Corcuera I; Rivera F; del Campo JM;
Clin Transl Oncol; 2012 Jul; 14(7):512-5. PubMed ID: 22721795
[TBL] [Abstract][Full Text] [Related]
59. Implementation of the 2021 molecular ESGO/ESTRO/ESP risk groups in endometrial cancer.
Imboden S; Nastic D; Ghaderi M; Rydberg F; Siegenthaler F; Mueller MD; Rau TT; Epstein E; Carlson JW
Gynecol Oncol; 2021 Aug; 162(2):394-400. PubMed ID: 34127276
[TBL] [Abstract][Full Text] [Related]
60. Update on prognostic markers for endometrial cancer.
Binder PS; Mutch DG
Womens Health (Lond); 2014 May; 10(3):277-88. PubMed ID: 24956294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
